Nivolumab-AVD outperforms BV-AVD in efficacy and safety, offering a promising frontline option for OAs with advanced classic Hodgkin lymphoma.
The post Reduced Toxicity and Better Survival With N-AVD in cHL first appeared on Physician’s Weekly.
Reduced Toxicity and Better Survival With N-AVD in cHL
Leave a Reply
We bring you the best Premium WordPress Themes that perfect for news, magazine, personal blog, etc. Check our landing page for details.